Latest GLP-1 Therapies Research Papers | OpenScience.ink

2 days ago • Problemy endokrinologii

Semaglutide may cause muscle loss through a hormone and cell growth pathway, affecting muscle sugar use and possibly leading to hard-to-control high blood sugar in type 2 diabetesSemaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.

Case Reports

2 days ago • The Journal of the Association of Physicians of India

Glucagon-based Treatments and Vision Loss Risks in India: Weighing Benefits and CautionsGlucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.

Article

2 days ago • Bioanalysis

Sensitive method to measure semaglutide levels in human blood plasmaDevelopment and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma.

📖 Top 50% JournalArticle

2 days ago • Problemy endokrinologii

Expert agreement on safely using semaglutide and tirzepatide for obesity treatment[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].

English Abstract

2 days ago • Clinical nutrition (Edinburgh, Scotland)

Higher blood levels of glucagon-like peptide-1 are linked to feeding problems after traumatic brain injuryElevated plasma glucagon-like Peptide-1 levels are associated with enteral feeding intolerance in traumatic brain injury.

Article

2 days ago • The Journal of the Association of Physicians of India

Real-World Experiences Using Semaglutide at a Hospital in JharkhandSemaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.

Observational Study

2 days ago • Global cardiology science & practice

Incretin therapies and PPARγ activators as regulators of fat hormone and antioxidant pathways in diabetes-related heart diseaseIncretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.

📖 Top 50% JournalArticle

2 days ago • Cureus

Effects of Glucagon-Like Peptide-1 Receptor Drugs on Reproductive Health for Obstetrician-GynecologistsGlucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists.

Article

2 days ago • Internal medicine (Tokyo, Japan)

Unusual Anorexia Nervosa After Weight-Loss Surgery and Diabetes Medication in a Patient with Severe Obesity and Type 2 DiabetesAtypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.

Article

2 days ago • Drug and alcohol dependence

Cannabis use and heart, kidney, and survival outcomes in people with type 2 diabetes treated with GLP-1 drugsCannabis use and cardiovascular, renal, and mortality outcomes in patients with type 2 diabetes receiving GLP-1 receptor agonists: A propensity score-matched cohort study.

🎖️ Top 10% JournalArticle

2 days ago • Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Known Links and Unanswered Questions Between Sleep and ObesitySleep and obesity-known interactions and open questions.

Article

2 days ago • Drug design, development and therapy

Side Effects Linked to Incretin-Based Diabetes Treatments: Causes, Care, and Risk ReductionAdverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.

📖 Top 20% JournalArticle

2 days ago • Molecular and cellular biochemistry

Liraglutide may improve energy production and gene regulation in diabetic kidney disease through the NQO1/SIRT3 pathwayLiraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease.

Article

2 days ago • Pediatric obesity

Use of Subsidized Semaglutide in Icelandic Children with Obesity in Real LifeReal-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.

📖 Top 20% JournalArticle

2 days ago • Childhood obesity (Print)

Protecting Muscle and Bone Growth and Physical Abilities in Teens Taking GLP-1 TreatmentProtecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.

📖 Top 30% JournalArticle

2 days ago • Annals of internal medicine

Weekly semaglutide lowers heavy drinking days after 26 weeks in people with alcohol use disorder and obesityIn alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.

🥈 Top 2% JournalArticle

2 days ago • Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA

GLP-1 drugs in hip, knee, and shoulder joint replacement: links to obesity, arthritis, metabolism, and surgery risksGLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.

🥉 Top 5% JournalEditorial

2 days ago • The British journal of ophthalmology

Semaglutide-linked vision loss may involve hidden optic nerve spots and long-term dehydrationSemaglutide-associated NAION: a proposed 'two-hit' model involving buried optic disc drusen and sustained hypohydration.

🎖️ Top 10% JournalArticle

2 days ago • Microbiology spectrum

Liraglutide's effects on changes in gut bacteriaEffects of liraglutide on gut bacterial community dynamics.

📖 Top 20% JournalArticle

3 days ago • Diabetes research and clinical practice

Guidelines for Increasing Injectable Treatments Beyond GLP-1 Therapy in Type 2 DiabetesGuideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes.

🎖️ Top 10% JournalArticle

3 days ago • Expert review of respiratory medicine

Sepsis risk in people with COPD and type 2 diabetes linked to new blood sugar treatmentsSepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies.

Article

3 days ago • International clinical psychopharmacology

Potential safety concerns and monitoring advice for lithium and GLP-1 treatments in bipolar disorderLithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.

📖 Top 30% JournalArticle

4 days ago • Indian journal of endocrinology and metabolism

Whey protein before breakfast may reduce blood sugar spikes and increase insulin response in type 2 diabetesEffect of Pre-breakfast Whey Protein Supplement on Post-breakfast Glycaemic Excursion and Insulinotropic Response in Type 2 Diabetes Mellitus.

📖 Top 50% JournalArticle

4 days ago • Frontiers in nutrition

Changes in eating experience during GLP-1 receptor agonist treatment explained by food enjoyment and desireAltered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour.

📖 Top 20% JournalArticle

4 days ago • Biology methods & protocols

Semaglutide use linked to milder COVID-19 and flu with improved kidney health after infectionSemaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.

📖 Top 30% JournalArticle

4 days ago • Research square

Mapping Communication Routes in the GLP-1 Receptor Using Molecular Simulations and Network AnalysisUncovering Allosteric Signaling Pathways of GLP-1R via Molecular Dynamics and Network Theory.

Preprint

4 days ago • Clinical nutrition ESPEN

Real-world study of how well tirzepatide works and how safe it is for people with obesityReal-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study.

📖 Top 30% JournalArticle

4 days ago • Appetite

Lowering sugar but keeping sweetness reduces blood sugar and hormone responses after eating differently in men and womenReducing sugar but preserving sweetness level of a sucrose solution attenuated postprandial glucose and incretin response in a sex-dependent manner.

📖 Top 20% JournalArticle

4 days ago • Public health reports (Washington, D.C. : 1974)

Adults’ Ability to Use Unprescribed Semaglutide Peptide Medications CorrectlyAbility of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.

🎖️ Top 10% JournalArticle

4 days ago • Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Glucagon-like peptide-1 receptor drugs and their link to diabetic eye disease: a review of outcomesGlucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.

📖 Top 20% JournalArticle

← prevpage 1 of 14next →